Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Hata

Showing results (211-220 of 264) with videos related to

Pageof 27
Sort By:
Cancer Discovery|April 7, 2021
Clinical Acquired Resistance to KRAS<sup>G12C</sup> Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK ReactivationNoritaka Tanaka, Jessica J Lin, Chendi Li, et al.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2021
Screening and Validation of Molecular Targeted RadiosensitizersHenning Willers, Xiao Pan, Nathalie Borgeaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2016
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective AnalysisJustin F Gainor, Alice T Shaw, Lecia V Sequist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2018
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of <i>EGFR</i>-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug TargetKyung-A Song, Yasuyuki Hosono, Crystal Turner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2020
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancerJ J Lin, S V Liu, C E McCoach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2018
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K InhibitionSandra Misale, Jackson P Fatherree, Eliane Cortez, et al.
NPJ Precision Oncology|August 18, 2020
Small cell transformation of <i>ROS1</i> fusion-positive lung cancer resistant to ROS1 inhibitionJessica J Lin, Adam Langenbucher, Pranav Gupta, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
A cellular and spatial atlas of <i>TP53</i> -associated tissue remodeling in lung adenocarcinomaWilliam Zhao, Benjamin Kepecs, Navin R Mahadevan, et al.
Nature Cancer|June 21, 2022
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancerAya Shiba-Ishii, Ted W Johnson, Ibiayi Dagogo-Jack, et al.
JCO Precision Oncology|August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung CancerZofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.
Pageof 27

Showing results (211-220 of 264) with videos related to

Sort By:
Pageof 27
Cancer Discovery|April 7, 2021
Clinical Acquired Resistance to KRAS<sup>G12C</sup> Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK ReactivationNoritaka Tanaka, Jessica J Lin, Chendi Li, et al.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2021
Screening and Validation of Molecular Targeted RadiosensitizersHenning Willers, Xiao Pan, Nathalie Borgeaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2016
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective AnalysisJustin F Gainor, Alice T Shaw, Lecia V Sequist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2018
Increased Synthesis of MCL-1 Protein Underlies Initial Survival of <i>EGFR</i>-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug TargetKyung-A Song, Yasuyuki Hosono, Crystal Turner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2020
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancerJ J Lin, S V Liu, C E McCoach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2018
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K InhibitionSandra Misale, Jackson P Fatherree, Eliane Cortez, et al.
NPJ Precision Oncology|August 18, 2020
Small cell transformation of <i>ROS1</i> fusion-positive lung cancer resistant to ROS1 inhibitionJessica J Lin, Adam Langenbucher, Pranav Gupta, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
A cellular and spatial atlas of <i>TP53</i> -associated tissue remodeling in lung adenocarcinomaWilliam Zhao, Benjamin Kepecs, Navin R Mahadevan, et al.
Nature Cancer|June 21, 2022
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancerAya Shiba-Ishii, Ted W Johnson, Ibiayi Dagogo-Jack, et al.
JCO Precision Oncology|August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung CancerZofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.
Pageof 27